Avanir Targets Watson In Suit Over Nuedexta Patents

Law360, New York (March 6, 2012, 12:49 PM EST) -- Avanir Pharmaceuticals Inc. sued drugmaker Watson Pharmaceuticals Inc. in Delaware on Friday in an effort to block plans to market a generic version of so-called involuntary emotion drug Nuedexta, the latest in a campaign of patent suits over the drug.

Avanir claims that New Jersey-based Watson's planned generic version of the drug — which is sold in capsule form and used to treat involuntary laughing and crying disorders in patients with underlying brain conditions — infringed two of its patents.

The California-based company contends it would...
To view the full article, register now.